SAFETY OF INOTERSEN TREATMENT IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHYNoel R. Dasgupta, Stephen B. Heitner, Jesse Kwoh et al.|Journal of the American College of Cardiology|2019Cited by 7
Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324)Thomas H. Brannagan, Morie A. Gertz, Annabel K. Wang et al.|Neurology|2018Cited by 2
Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) (N2.001)Morie A. Gertz, Merrill D. Benson, Annabel K. Wang et al.|Neurology|2018Cited by 1
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D. Benson, Teresa Coelho, Márcia Waddington‐Cruz et al.|Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)|2018Cited by 0
Inotersen Improves Norfolk Quality of Life-Diabetic Neuropathy Measures in Patients With Hereditary Transthyretin Amyloidosis with Polyneuropathy in the Phase 3 Study NEURO-TTR (S5.006)Michael Polydefkis, Annabel K. Wang, Teresa Coelho et al.|Neurology|2018Cited by 0